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Articular cartilage defects do not regenerate. Transplanta-
tion of autologous articular chondrocytes, which is clini-
cally being performed since several decades, laid the foun-
dation for the transplantation of genetically modified cells, 
which may serve the dual role of providing a cell popula-
tion capable of chondrogenesis and an additional stimu-
lus for targeted articular cartilage repair. Experimental data 
generated so far have shown that genetically modified ar-
ticular chondrocytes and mesenchymal stem cells (MSC) 
allow for sustained transgene expression when transplant-
ed into articular cartilage defects in vivo. Overexpression of 
therapeutic factors enhances the structural features of the 
cartilaginous  repair  tissue.  Combined  overexpression  of 
genes with complementary mechanisms of action is also 
feasible, holding promises for further enhancement of ar-
ticular cartilage repair. Significant benefits have been also 
observed in preclinical animal models that are, in princi-
ple, more appropriate to the clinical situation. Finally, there 
is convincing proof of concept based on a phase I clinical 
gene therapy study in which transduced fibroblasts were 
injected into the metacarpophalangeal joints of patients 
without adverse events. To realize the full clinical poten-
tial of this approach, issues that need to be addressed in-
clude its safety, the choice of the ideal gene vector system 
allowing for a long-term transgene expression, the iden-
tification  of  the  optimal  therapeutic  gene(s),  the  trans-
plantation without or with supportive biomaterials, and 
the establishment of the optimal dose of modified cells. 
As safe techniques for generating genetically engineered 
articular chondrocytes and MSCs are available, they may 
eventually represent new avenues for improved cell-based 
therapies for articular cartilage repair. This, in turn, may pro-
vide an important step toward the unanswered question 
of articular cartilage regeneration.
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In the early 1990s, Christopher H. Evans proposed and im-
plemented the idea of using genetically modified cells for 
the treatment of arthritis (1). When synovial cells modified 
ex vivo via retroviral vector gene transfer were injected into 
the metacarpophalangeal joints of patients with rheuma-
toid arthritis, an interleukin-1 receptor antagonist (IL-1Ra), 
the active transgene product, was successfully expressed 
and biologically active (2). This study confirmed the feasi-
bility and laid the basis for the clinical application of ge-
netically modified cells to human joints (3). Since then, 
considerable progress has been made toward our under-
standing of the biological and technological requirements 
for  a  successful  transplantation  of  genetically  modified 
cells overexpressing secreted therapeutic proteins in vitro 
and in vivo.
An articular cartilage defect is an area of damaged or miss-
ing  cartilage.  Although  often  caused  by  acute  trauma, 
cartilage defects may also occur as a result of osteoarthri-
tis,  osteonecrosis,  osteochondritis  dissecans,  and  other 
pathologies (4). While traumatic defects usually are well 
defined and surrounded by normal articular cartilage, de-
fects caused by osteoarthritis are often ill-defined, large, 
and surrounded by osteoarthritic tissue of variable quality. 
When restricted to the articular cartilage, the defects are 
termed chondral and when they reach into the subchon-
dral bone, they have an osteochondral nature. In contrast 
with  the  very  limited  repairability  of  chondral  defects 
(that are only partly repopulated by cells from the synovial 
membrane), osteochondral defects are filled with a bone 
marrow clot that serves as a basis for the cartilaginous re-
pair tissue that is formed by pluripotent undifferentiated 
mesenchymal  stem  cells  (MSC)  arising  from  the  bone 
marrow. Such articular cartilage defects may lead to the 
development of osteoarthritis. Since degenerative joint 
diseases affect more than a third of the world population 
and disorders of the articulations, in general, account for 
more than half of all chronic conditions in persons aged 
60 years and over, optimized treatment strategies for ar-
ticular cartilage lesions are of a high socio-economic im-
portance (5).
Symptomatic cartilage defects require surgical treatment. 
Treatment  options  include  marrow-stimulating  tech-
niques such as microfracture, Pridie drilling and abrasion 
arthroplasty,  autologous  chondrocyte  transplantation, 
and the transfer of both autologous or allogeneic osteo-
chondral transplants (6). Autologous chondrocyte trans-
plantation involves the isolation and culture of articu-
lar chondrocytes that are subsequently implanted 
in conjunction with a supportive biodegradable matrix 
into  the  articular  cartilage  defect.  Several  recent  rand-
omized controlled clinical studies confirmed the poten-
tial of autologous chondrocyte transplantation to repair 
large chondral defects (6). These promising data have laid 
a clinical basis for the experimental transplantation of ge-
netically modified cells. In the past decades, considerable 
progress has been made to establish the scientific founda-
tion for the use of such modified cells. In particular, articu-
lar chondrocytes and, more recently, MSCs have been ge-
netically modified using nonviral or viral methods. When 
used in model systems of articular cartilage defects, these 
cells provide chondrogenic factors selectively stimulat-
ing chondrogenic processes, such as precursor cell and 
chondrocyte proliferation and/or the synthesis of extra-
cellular matrix components like type-II collagen and pro-
teoglycans. Moreover, in small and large animal models, 
transplantation of genetically modified cells has resulted 
in significant structural improvements in the repair tissue. 
Genetic modification of cells may therefore improve their 
therapeutic potential by selectively delivering biological-
ly active compounds to a site of an articular cartilage de-
fect. Moreover, genetically modified cells may serve the 
dual role of providing a repair stimulus to the host tissue 
and a target cell population that is capable of chondro-
genesis (7).
The aim of this review is to outline options for genetic ma-
nipulation of target cells for articular cartilage repair, pri-
marily articular chondrocytes and MSCs, and the current 
progress  in  adapting  strategies  based  on  chondrocyte 
transplantation  for  the  delivery  of  genetically-modified 
cells for clinical use to treat focal articular cartilage defects 
and osteoarthritis.
GENE TRANSFER IN PRECURSOR CELLS AND ARTICULAR 
CHONDROCYTES
In the past two decades, articular chondrocytes and MSCs 
have been successfully transplanted into articular cartilage 
defects in patients, with the aim of improving articular car-
tilage  repair.  MSCs  display  some  advantages  compared 
with differentiated cells that make them attractive targets 
for manipulation in the goal of cartilage and bone regen-
eration. They can be easily isolated in a noninvasive and 
abundant manner from various tissues like the bone mar-
row, bone, adipose tissue, muscle, synovium, periosteum, 
and perichondrium (7)). They have a potential for self-re-
newal and to give rise to different tissues under adapted 
stimuli (cartilage, bone, adipose tissue). Also, their multilin-247 Madry and Cucchiarini: Use of genetically modified cells for articular cartilage repair
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eage potential can be maintained in culture over time, in 
contrast to chondrocytes that lose their phenotype in such 
conditions.  Remarkably,  MSCs  have  immunosuppressive 
properties that might permit allo- and xenotransplanta-
tion. Preliminary clinical studies have shown the benefits of 
transplanting progenitor cells in human cartilage defects 
for instance, allowing for the formation of a stable repair 
tissue of fibrocartilaginous quality. As these cells, in par-
ticular articular chondrocytes, are relatively permissive to 
a variety of gene transfer systems, including nonviral and 
viral methods, researchers and clinicians have begun to 
evaluate the effect of gene transfer using a range of po-
tentially therapeutic gene products. Other potential tar-
get cells for genetic modification and subsequent trans-
plantation include cells from the tissues surrounding the 
joint such as cells of the synovial lining, bone, muscle, 
tendons, ligaments, and menisci.
Gene transfer using various reporter gene sequences has 
been successfully achieved in all these cell types by ap-
plication of either nonviral compounds (8-20) or of viral 
vectors based on adenoviruses (8,11,21-38), retroviruses 
(8,11,21,25,39-44),  and  recombinant  adeno-associated 
viruses (rAAV) (11,45-66). The latter vectors are currently 
the most potent gene delivery vehicles available, as they 
can efficiently and durably transduce articular chondro-
cytes  (45,47,48,54-57),  MSCs  (45,46,58,59),  synoviocytes 
(49-53), and other relevant cells constituting surrounding 
tissues (11,60-66) compared with the relatively less effi-
cient nonviral vectors, the more immunogenic adenoviral 
vectors that also show very short-term gene expression 
capability, and the retroviral vectors that require division 
and pre-selection of the target cells for practicability (7). 
Another important point to consider in a human gene 
therapy trial is the ability of retroviral vectors to integrate 
into the host genome that might possibly lead to events 
of insertional mutagenesis and undesirable activation of 
tumor genes. Again to their advantage, rAAV vectors have 
been shown to be mostly maintained under stable episo-
mal forms (67).
Key  principles  applied  for  gene-based  approaches  in-
clude the stimulation of anabolic pathways to enhance 
chondrogenesis,  eg,  cell  proliferation  and  synthesis  of 
extracellular matrix and the inhibition of catabolic path-
ways to prevent degradation (Table 1) (7). Among the 
gene candidates of value for articular cartilage repair, in-
hibitors of both matrix-degrading enzymes (tissue inhibi-
tor of metalloproteinases) (9,68) and of proinflammatory 
cytokines (IL-1Ra, the soluble receptors sIL-1R, or sTNFR) 
(22,35,40,51,70), as well as chondroprotective cytokines 
(IL-4 and -10) (19,49,71) have been applied to inhibit cata-
bolic pathways in vitro that are potentially activated in 
response to cartilage damage or injury. More relevant 
for the induction of cartilage repair, single or combined 
administration of components of the cartilage matrix or 
of the enzymes that synthesize them (77,78), of growth 
factors  and  their  receptors  (IGF-I,  FGF-2,  BMPs,  TGF-β) 
(12,19,20,23,28-30,32,35,36,45,72,73),  and  of  transcrip-
tion factors (SOX5, SOX6, SOX9) (15,21,34,44,56,57) was 
successfully employed to activate anabolic processes in 
vitro. Alternatively, restoration of cell vitality and activa-
tion of proliferation in vitro have been achieved by ap-
plication of IGF-I and FGF-2 (9,12,20,45,57,72), telomerase 
(hTERT) (75), inhibitors of apoptosis (bcl-2) (74), or HSP70 
(16). Interestingly, approaches that influence several of 
these processes have been also successfully attempted, 
like combining the transfer of inhibitors of catabolism 
pathways and of activators of anabolic events (IGF-I/IL-
1Ra or IGF-I/IL-4) (19,35,36), as well as that of activators 
of anabolic and proliferative processes (FGF-2/SOX9 
or FGF-2/IGF-I) (57).
TAbLE 1. Principles, mechanisms of action and gene candi-
dates for articular cartilage repair
Mechanism of action Target gene References
Inhibition of catabolic 
pathways
inhibition of matrix-degrading 
enzymes
TIMP (68,69)
inhibition of proinflammatory 
cytokines
IL-1Ra, sIL-1R, 
sTNFR
(22,35,40,51,70)
chondroprotective cytokines (IL-4, IL-10) (19,49,71)
Stimulation of anabolic 
pathways
growth factors IGF-I, FGF-2, 
BMPs, TGF-β
(12,19,20,23,28-30-
,32,35,36,45,72,73)
chondrogenic transcription 
factors
SOX5, SOX6, 
SOX9
(15,21,34,44,56,57)
Cytoprotection/proliferation
growth factors IGF-I, FGF-2 (9,12,20,45,57,72)
inhibition of apoptosis bcl-2, HSP70 (16,74)
catalytic component of human 
telomerase
human 
telomerase
(75)
Combinatorial approaches
inhibition of catabolic pathways 
plus activation of anabolic 
pathways
IGF-I/IL-1Ra;
IGF-I/IL-4
(19,35,36)
activation of anabolic plus prolif-
erative pathways
FGF-2/SOX9;
FGF-2/IGF-I
(57,76)
*TIMP – tissue inhibitor of metalloproteinases.REVIEW ARTICLE 248 Croat Med J. 2011; 52: 245-61
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TRANSPLANTATION OF GENETICALLY MODIFIED CELLS 
ONTO NORMAL ARTICULAR CARTILAGE EXPLANTS IN 
VITRO
Transplantation  of  genetically  engineered  articular 
chondrocytes onto articular cartilage explants allows for 
the repopulation of articular cartilage and the creation of 
chimerical articular surfaces in vitro (12,20,70,79,80) (Fig-
ure 1). A prerequisite for such a transplantation approach 
is the adherence and integration of the cells to the articu-
lar surface with continuous expression of the transgene. 
Enzymatic treatment of the articular surface results in an 
intimate integration of the transplanted cells with the ar-
ticular cartilage, facilitating the formation of the interface 
between the two tissues (20,81). Transgenes have been 
shown to be active for at least 2 weeks in vitro, a time frame 
sufficient to allow for structural changes. While researchers 
usually transplant cells that have been genetically modi-
fied, Doherty et al have demonstrated that transplanted 
articular chondrocytes are amendable as late as 35 days af-
ter transplantation to adenoviral gene transfer in vitro (79).
The new tissue that forms is characterized by the presence 
of type-II collagen and proteoglycans and by the absence of 
type-I collagen. In this model, transplantation of chondro-
cytes overexpressing BMP-7 resulted in a thicker new tissue 
layer (80). Overexpression of a human IGF-I cDNA by ge-
netically engineered articular chondrocytes simultaneously 
promoted chondrogenesis and shifted the cartilage home-
ostasis toward an anabolic direction, as demonstrated by 
the increased rates of cell proliferation and of extracellular 
matrix synthesis in the new tissue layer (20). Remarkably, 
synthesis of DNA and of glycosaminoglycans was also stim-
ulated in the underlying explant cartilage. When fibroblast 
growth factor 2 (FGF-2), a mitogen for chondrocytes, was 
applied by transfected chondrocytes, the proliferative ac-
tivities were stimulated in the new tissue without effect 
upon matrix glycosaminoglycan synthesis (12). These data 
suggest that therapeutic FGF-2 gene transfer may be ap-
plicable for the treatment of cartilage defects when cellular 
repopulation is the therapeutic goal, while BMP-7 may have 
value  to  enhance  matrix  synthesis  and  IGF-I  for  circum-
stances demanding a balanced increase in both chondro-
cyte proliferation and matrix synthesis.
Gene transfer of transcription factors has received recent 
interest because of the impact of these molecules on chon-
drogenesis. Overexpression of SOX9 via retroviral transduc-
tion was shown to stimulate type-II collagen expression in 
pellet cultures of human osteoarthritic articular chondro-
cytes (44) and in human osteoarthritic articular chondro-
cytes embedded in alginate spheres (21,56,57).
Figure 1.
Macroscopic view (A) and histologic section (B) of a composite culture/ex vivo articular chondrocyte transplantation model of a chondral (partial-
thickness) defect. (A) Bovine articular chondrocytes were transfected with the lacZ-plasmid vector pCMVßgal and transplanted into the partial-
thickness chondral defect created in a normal bovine cartilage explant. The borders of the circular chondral defect can be easily identified. The 
transplanted chondrocytes express the transgene on day three post-transfection which can be identified by the intensive blue color. (B) Photo-
micrograph of the integration site of the new tissue that has formed based on the transplantation of ex vivo genetically modified chondrocytes 
with the neighboring articular cartilage. Note the good integration of these two tissues, the relative hypercellularity of the new repair tissue based 
on the genetically modified cells in comparison with the neighboring articular cartilage, which exhibits a loss of safranin O staining at his edge 
toward the defect as a result of the surgically induced lesion. Original magnification ×100 (B).249 Madry and Cucchiarini: Use of genetically modified cells for articular cartilage repair
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TRANSPLANTATION OF GENETICALLY MODIFIED CELLS 
TO FOCAL ARTICULAR CARTILAGE DEFECTS IN VIVO
In this section, a number of recent studies in the field of 
articular cartilage repair are highlighted, with an emphasis 
on preclinical approaches that appear to hold most prom-
ises for a possible clinical translation.
Transplantation of genetically modified cells into articular 
cartilage defects in vivo has been performed in three-di-
mensional systems, including cell aggregates such as co-
agulated  bone  marrow  aspirates  (82),  by  encapsulation 
of genetically engineered cells in supportive biomaterials 
like alginate (9,10,83) (Figure 2), agarose (84,85), fibrin or 
type-I collagen gels without (86-88) or with a periosteal 
flap (48,89), synthetic biodegradable scaffolds (90-92), and 
as  genetically  modified  tissue-engineered  cartilage  (7). 
Kang et al were the very first to transplant chondrocytes 
genetically modified by a retroviral vector into an articu-
lar cartilage defect in vivo (93). Others used nonviral (94-
96), adenoviral (70,82,87), retroviral (93,97-100), and rAAV 
vectors (101) to deliver reporter genes to defects via ex 
vivo approaches. While articular chondrocytes are usually 
transplanted (87,93,94,96,100,102,103), fibroblasts (76,104), 
perichondrial (95), periosteal (97,101), muscle-derived cells 
(98), or NIH 3T3 cells (76) have been also applied. Animal 
models for these marker gene studies included rats (87), 
rabbits (9,10,48,76,82-84,86,88,90-101,103,104), goats (89), 
and horses (102).
A prerequisite for the transplantation of genetically modi-
fied cells for articular cartilage repair is their capability to 
secrete pharmacologically active amounts of the recom-
binant protein (7). Yet, the cell type used for transplanta-
tion, the efficiency of the gene delivery method, and the 
possible influence of the biomaterial used for cell encapsu-
lation critically affect the amount of a therapeutic protein 
that is produced and secreted (Figure 3). For example, IGF-I 
production by bovine articular chondrocytes transfected 
with a lipid-based method was reported to be 83 ng/107 
cells/24 hours (20), while 92 ng IGF-I/107 cells/24 hours 
were secreted by a retrovirally transduced bovine mam-
mary epithelial cell line selected for cells carrying the trans-
gene (105), less than the 560 ng IGF-I/107 cells/24 hours 
produced by keratinocytes after retroviral transduction and 
selection (106). Normal human dermal fibroblasts similar-
ly retrovirally transduced secreted 39 ng IGF-I/107 cells/24 
hours but 214 ng IGF-I/107 cells/24 hours when encapsu-
lated in alginate microspheres (107). When human normal 
and osteoarthritic articular chondrocytes were transduced 
with an rAAV IGF-I vector, 27 and 19 ng IGF-I/107 cells/24 
hours were secreted (our unpublished data).
Figure 2.
Principle of alginate encapsulation of transfected, genetically modified articular chondrocytes. The alginate beads are implanted in a subchon-
dral location. Overexpression of a therapeutic transgene results in autocrine and paracrine signals targeting the cells within the alginate sphere. 
When the protein is secreted, paracrine effects may stimulate the repair tissue that forms in the defect, the neighboring normal articular cartilage 
and, via the synovial fluid, other cells of the joint such as cells of the synovial lining and periosteal cells. In parallel, the transplanted cells are 
also stimulated by factors from the host. The alginate sphere is thought to protect the transplanted cells from immune responses.REVIEW ARTICLE 250 Croat Med J. 2011; 52: 245-61
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Transgenes expressed via such ex vivo strategies remained 
active for about one month in the cartilage defects, sig-
nificantly longer compared with the application of recom-
binant  proteins.  One  of  the  earliest  examples  was  pro-
vided by Mason et al who transferred the BMP-7 growth 
factor gene into a focal defect using periosteal cells trans-
duced with a retroviral vector attached to a polyglycolic 
acid scaffold (39). As shown in this study, articular carti-
lage repair was improved at 8 and 12 weeks in vivo. A va-
riety of therapeutic genes like BMP-2, BMP-7, IGF-I, FGF-2, 
and  TGF-β  (7,9,10,76,108-113)  has  been  studied  so  far, 
with significant improvements in articular cartilage repair 
(7,9,10,76,108,110-113) (Figure 4). The choice of therapeu-
tic genes is based on the strategy selected for improving 
articular cartilage repair. This, in theory, implies the use of 
genes that either stimulate chondrogenesis or inhibit ar-
ticular  cartilage  degeneration.  While  the  first  approach 
has been studied in numerous investigations and is later 
described, the latter approach has been mainly tested in 
model systems of osteoarthritis so far. More specifically, 
strategies for improving individual parameters of chon-
drogenesis can be tailored. For example, IGF-I, a fac-
tor that simultaneously stimulates type-II collagen and pro-
teoglycan synthesis as well as cell proliferation, may be of 
interest for strategies aiming at a balanced enhancement 
of these parameters (20), while FGF-2, which is mitogenic, 
may be useful to increase the pool of cells in a cartilage de-
fect responsive to chondrogenesis (12). Initially, most of the 
evaluations were carried out in small animal models, such 
as rats (108,112) and rabbits (9,10,76,110,113). Hidaka et al 
(102) and Goodrich et al (114) performed the implantation 
of chondrocytes overexpressing BMP-7 or IGF-I in horses, 
respectively. Allogeneic chondrocytes transduced by an 
adenoviral vector carrying BMP-7 implanted into defects 
allowed for a better appearance of the repair tissue after 4 
weeks, although no differences were found between the 
groups after 8 months (102). Goodrich et al showed that 
arthroscopically-grafted  chondrocytes  genetically  modi-
fied by an adenovirus vector encoding equine IGF-I signifi-
cantly increased IGF-I mRNA and ligand production in re-
pair tissue in an equine model for up to 9 weeks following 
transplantation (114). Collagen type II expression in IGF-I 
treated defects was significantly increased and correlated 
with increased collagen type II immunoreactivity. In addi-
tion, genetic modification of chondrocytes prior to trans-
plantation improved early (4 to 9 weeks), and to a lesser 
degree long-term, cartilage repair over control defects in 
vivo (114). Others used genetically engineered MSCs over-
expressing growth factors such as BMP-4-transduced cells 
provided with fibrin glue in full-thickness chondral defects 
in rabbits (115). Histologic repair was significantly improved 
in defects receiving cells modified to overexpress BMP-4 
compared with those where they carried a marker gene. 
Also, MSCs overexpressing TGF-β1 seeded into polylactide 
scaffolds improved extracellular matrix formation, reconsti-
tution of the subchondral bone, and inhibited inflamma-
tory responses (116). Finally, transplantation of MSCs trans-
fected with the CDMP1 gene also enhanced the repair of 
osteochondral defects (117).
More recently, Ivkovic et al (118) implanted autologous 
bone marrow clots containing ex vivo adenovirally-trans-
duced cells with a TGF-β1-expressing vector into partial-
thickness chondral defects in sheep. Remarkably, improved 
histological, biochemical, and biomechanical parameters 
were evident in this preclinical animal model 6 months 
postoperatively.
Taken  together,  the  current  literature  supports  several 
conclusions illustrating the recent progress that has been 
made in developing approaches for the transplantation of 
genetically modified cells (eg, articular chondrocytes and 
Figure 3.
Secretion  of  human  insulin-like  growth  factor  I  by  bovine  articu-
lar chondrocytes and NIH 3T3 cells transfected with FuGENE 6, 
by transduced bovine mammary epithelial cell line and by kerati-
nocytes, both after retroviral transduction and selection, by human 
dermal fibroblast transduced with a retroviral vector, and by human 
normal and human osteoarthritic articular chondrocytes transduced 
with an rAAV-hIGF-I.251 Madry and Cucchiarini: Use of genetically modified cells for articular cartilage repair
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MSCs) as a therapeutic option for human articular carti-
lage defects. First, there is convincing proof of principle 
that articular chondrocytes and MSCs modified by differ-
ent nonviral and viral approaches can be transplanted into 
articular cartilage defects in vivo, allowing for sustained 
and clinically relevant transgene expression levels. Second, 
overexpression of therapeutic proteins enhances the struc-
tural features of the repair tissue of the articular cartilage 
and subchondral bone, being superior to unmodified or 
mock-transduced/-transfected cells. Third, combined over-
expression of genes with complementary mechanisms of 
action (eg, chondrogenic and proliferative factors) is feasi-
ble, holding promises for further enhancement of articular 
cartilage repair. Fourth, significant benefits have been ob-
served in preclinical animal models that are, in principle, 
more appropriate to study the situation in patients.
TRANSPLANTATION OF GENETICALLY MODIFIED CELLS 
ONTO OSTEOARTHRITIC CARTILAGE EXPLANTS IN 
VITRO
Ex vivo modified cells may be also applied for the resurfac-
ing of the disrupted cartilage matrix in early stages of oste-
oarthritis. When transplanted onto the surface of osteoar-
thritic human cartilage, the modified chondrocytes may fill 
the gaps between the fissures, cracks, and other surface 
discontinuities (Figure 5). Since osteoarthritis is character-
ized in part by the activation of inflammatory and catabol-
ic processes, such pathways might be inhibited by apply-
ing chondrocytes, MSCs, or synoviocytes overexpressing 
inhibitory molecules, such as IL-1Ra alone (70,119-124) or 
combined with IL-10 (124).
Baragi et al were the first to show that transplantation of 
human osteoarthritic chondrocytes transduced with ade-
noviral vectors to overexpress the human IL-1Ra onto the 
articular surface of osteoarthritic cartilage explant cultures 
was capable of protecting the cartilage from IL-1-induced 
extracellular  matrix  degradation  (70).  Remarkably,  trans-
duced, transplanted chondrocytes secreted significant lev-
els of biologically active IL-1Ra that were sufficient to allow 
for a resistance to IL1-induced proteoglycan degradation 
over the 10-day culture.
We transplanted bovine articular chondrocytes transfected 
with a nonviral vector overexpressing the E.coli lacZ gene 
onto  the  articular  surface  of  human  osteoarthritic  carti-
lage  explant  cultures  (Figure  5). Transfected,  transplanted 
chondrocytes settled into the clefts of the osteoarthritic car-
tilage and restored a relatively even articular cartilage surface 
populated by the transplanted cells over the 7-day culture.
TRANSPLANTATION OF GENETICALLY MODIFIED CELLS 
IN MODELS OF OSTEOARTHRITIS IN VIVO
Transplantation of genetically modified cells in experi-
mental models of osteoarthritis in vivo has been mostly 
carried out by intra-articular injection of genetically 
Figure 4.
Cartilage repair three weeks after transplantation of genetically modified NIH 3T3 cells into an osteochondral defect model in the trochlea grove 
of rabbits. (A) Defect treated with the lacZ gene as a control. Note the remnants of the alginate sphere at the bottom of the defect. The repair 
tissue is largely negative for safranin O staining, indicating a lack of proteoglycans. (B) Contralateral knee of the same animal treated with the 
IGF-I gene. Although the margins of the defect can be still distinguished, a repair tissue rich in proteoglycans has been formed. Original mag-
nification ×40.REVIEW ARTICLE 252 Croat Med J. 2011; 52: 245-61
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modified cells, an approach also employed in experimen-
tal models of rheumatoid arthritis (125).
Pelletier et al (123) were among the first groups to inject 
retrovirally-modified synoviocytes to overexpress an IL-1-
Ra in a model of osteoarthritis in dogs, showing the suc-
cessful reduction of the progression of the experimentally 
induced lesions. The same IL-1Ra gene sequence, provid-
ed alone or in combination with IL-10 via synoviocytes 
transduced with a retroviral vector was of further benefit 
to treat osteoarthritic in rabbits in vivo (124). More recent-
ly, Matsumoto et al (126) reported the efficacy of inject-
ing intra-articularly muscle-derived stem cells modified by 
combined gene transfer of BMP-4 with sFlt1 (a vascular en-
dothelial growth factor antagonist) for cartilage repair in a 
rat model of osteoarthritis.
In summary, there is a scarcity of experimental studies of 
transplanting genetically modified cells in models of os-
teoarthritis in vivo and, most importantly, none of the ap-
proaches described here for the treatment of osteoarthritis 
have been evaluated in large animal models to date.
CLINICAL GENE THERAPY TRIALS USING GENETICALLY 
MODIFIED CELLS
Preclinical  data,  as  those  described  above,  have  en-
couraged the initiation of human clinical trials origi-
nally for arthritis, mostly based on the transfer of an IL-1Ra 
gene sequence (1,2,127-136) and of a sTNFR fusion protein 
(129,130,132,135,137-140)  in  the  joints  of  patients  with 
rheumatoid arthritis. Proof of concept and safety has been 
already established in the phase I clinical gene therapy 
study by Chris Evans in the USA and Peter Wehling in Ger-
many (2). Autologous synovial fibroblasts transduced with 
a retroviral vector encoding for an IL-1Ra cDNA were inject-
ed into the 2nd-5th metacarpophalangeal joints of 9 post-
menopausal women with advanced rheumatoid arthritis. 
Elevated amounts of IL-1Ra were present in the synovial 
fluid of treated patients, and cells expressing high levels of 
IL-1Ra were found in the synovial membrane. There were 
no adverse events. This investigation highly encouraged 
further development of gene-based approaches for the 
treatment of cartilage disorders. Regarding osteoarthritis, 
a phase I protocol is currently ongoing, based on an ex 
vivo approach using the retroviral transfer of transforming 
growth factor (TGF)-beta (130).
CHALLENGES FOR THE CLINICAL APPLICATION OF 
TRANSPLANTING GENETICALLY MODIFIED CELLS TO 
PROMOTE ARTICULAR CARTILAGE REPAIR
In conclusion, transplantation of genetically modified cells 
is a promising tool for the treatment of articular cartilage 
defects such as resulting from trauma or osteoarthritis. In 
the past decades, considerable progress has been made to 
Figure 5.
Photomicrograph of human osteoarthritic cartilage after transplantation of genetically modified bovine articular chondrocytes. Articular chondro-
cytes transfected with the lacZ gene have been seeded onto the surface of early stage human osteoarthritic cartilage. Note how the transplanted 
chondrocytes are filling the voids between the fragmented cartilage of the surface. Foci of transplanted chondrocytes expressing the transgene 
are identifiable by their blue color. (A) Overview and (B) high magnification of the integration between the newly formed tissue based on geneti-
cally modified chondrocytes and the original osteoarthritic surface. Safranin O-fast green. Original magnification ×100 (A) and ×200 (B).253 Madry and Cucchiarini: Use of genetically modified cells for articular cartilage repair
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lay the scientific foundation for the use of modified cells. In 
particular, articular chondrocytes and, more recently, MSCs 
have  been  genetically  modified  using  nonviral  or  viral 
methods. When used in model systems of cell transplanta-
tion, structural improvements occurred in the new repair 
tissue. Moreover, in small animal models, transplantation of 
genetically modified cells has yielded significant structural 
improvements of the repair tissue. Lately, preclinical animal 
models have been applied to study the effects of overex-
pression of therapeutic genes (118). However, to realize the 
full potential of these approaches in the clinics, the follow-
ing issues have to be addressed:
1. the proof of the safety of this approach in preclinical and 
clinical trials
2. the choice of the ideal gene vector system
3. the choice of the optimal therapeutic gene(s)
4. the delivery without (eg, for large osteoarthritic lesions) 
or with a supportive biomaterial (for focal lesions),
5. the establishment of the optimal cell dose.
For traumatic cartilage defects, single or combined over-
expression  of  therapeutic  genes,  including  growth  and 
transcription factors, is feasible and results in structural im-
provements. Significant data have been collected in ani-
mal models of chondral and osteochondral defects. For os-
teoarthritis, transplantation approaches using genetically 
engineered cells have been less developed. Ex vivo models 
have already convincingly shown that genetically modified 
chondrocytes adhere to human osteoarthritic cartilage ex-
plants, and that inhibition of matrix degradation is possi-
ble. Animal studies using genetically modified cells for the 
treatment of osteoarthritis have mainly relied on the intra-
articular injection of these cells, making a specific targeting 
of osteoarthritic areas difficult. Moreover, it remains to be 
seen whether areas of cartilage loss may be repopulated 
by such approaches, considering that the nature of the os-
teoarthritic loss of articular cartilage is unknown and since 
a simple injection of cells alone does not address other fac-
tors involved in the pathogenesis of osteoarthritis such as 
mechanical overload induced by axial malalignment.
Several gene transfer systems are capable of successfully 
modifying articular chondrocytes and MSCs, the two most 
promising cell types for transplantation approaches. How-
ever, each of the individual vector system has intrinsic limi-
tations with regard to their efficacy (nonviral systems) and 
safety (eg, adenoviral systems) for human clinical applica-
tions. Most experts predict that initial human gene therapy 
trials based on the transplantation of genetically modified 
cells for articular cartilage repair will be conducted using 
rAAV  vectors. The  development  of  novel  (third  genera-
tion) adenoviral vectors may be another option, although 
significantly less immunogenic responses might be elicit-
ed when using rAAV. Vectors showing a capacity for site-
specific integration have been designed for the purpose 
of achieving long-term gene expression, such constructs 
have not been tested yet in articular cartilage repair set-
tings.
Supportive biomaterials may be used to deliver the ge-
netically modified cells to focal articular cartilage defects, 
similar  to  the  current  clinical  practice  of  treating  carti-
lage  lesions  with  matrix-assisted  autologous  chondro-
cyte  transplantation,  a  technique  in  which  the  articular 
chondrocytes are attached to different types of scaffolds, 
eg, based on collagen types I/III, hyaluronic acid, polygla-
ctin/poly-p-dioxanon, and fibrin-hyaluronan (141). Such a 
delivery of genetically modified chondrocytes in conjunc-
tion with biomaterials may be advantageous compared to 
cell delivery alone, as it allows for a spatially controlled ap-
plication of the modified cells to enhance chondrogenesis. 
An overexpression of therapeutic genes in such tissue-en-
gineered constructs offers the important advantage of a 
complete filling of the defect with a construct actively sup-
porting  chondrogenesis.  Although  possible  side-effects 
intrinsic to the biomaterial on transgene expression have 
to be ruled out in experimental studies, the current clinical 
consensus on the broad advantages of matrix-assisted au-
tologous chondrocyte transplantation suggest that genet-
ically modified cells may rather be delivered in supportive 
biomaterials to focal cartilage defects. For the treatment 
of osteoarthritis, however, no conclusions can be drawn at 
the moment because of the paucity of experimental pre-
clinical and clinical in vivo data.
Possible  side-effects  have  also  to  be  considered. While 
intra-articular injection of an BMP-2 adenoviral vector re-
sulted in the formation of osteophytes and spread of the 
vector DNA to the liver, lung, and spleen, no such effects 
were observed when an ex vivo approach was selected in-
jecting modified cells overexpressing BMP-2 instead (31). 
In fact, it appears that the therapeutic protein may exert 
its role in close proximity to the defect, as judged by the 
absence of elevated protein levels in the synovial fluid and 
peripheral blood and by the detection of only a few days 
of marker gene activity in cells adjacent to the site of the 
surgical approach.
The selection of therapeutic genes to specifically ad-
dress individual parameters of chondrogenesis will REVIEW ARTICLE 254 Croat Med J. 2011; 52: 245-61
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continue to be a challenge. Progress may come from more 
insights into the regulation of chondrogenesis, eg, using 
genomic and proteomic profiles.
Open questions remain also in terms of finding the optimal 
cells dose. In the clinical protocols of autologous chondro-
cyte transplantation, chondrocytes are usually transplant-
ed at densities of about 1 × 106 cells/cm2. When geneti-
cally modified articular chondrocytes overexpressing IGF-I 
were applied in a lapine model, about 75 × 106 cells/cm2 
were applied, a 75-fold higher dose (10). In the clinical gene 
therapy study by Chris Evans, 1 × 106 (low dose), 1.5-5 × 106 
(intermediate dose), and 6.5-10 × 106 (high dose) autolo-
gous synovial fibroblasts transduced with a retroviral vec-
tor encoding for an IL-1Ra cDNA were injected into meta-
carpophalangeal joints (2). Because of its similarity with the 
protocol currently used for autologous chondrocyte trans-
plantation, it is likely that a dose of 1 × 106 cells/cm2 may 
be elected as a starting point of evaluation when geneti-
cally modified chondrocytes will be transplanted to focal 
cartilage defects in patients.
Nevertheless,  nearly  three  decades  of  experimental 
and clinical research to advance the principles of articu-
lar chondrocyte transplantation have yielded significant 
technical improvements of clinical articular chondrocyte 
transplantation, such as chondrocyte application in highly 
specialized scaffolds for optimal cell attachment and dis-
tribution in vivo (141). Many of the procedures required 
to constitute such ex vivo gene transfer approaches are 
already available for the orthopaedic surgeon. For exam-
ple, cell (chondrocyte) isolation and in vitro cell culture – 
essential steps of such ex vivo protocols – are already in 
place. Moreover, the problem of the loss of the chondro-
cytic phenotype – as observed after prolonged monolayer 
culture (142), has been sufficiently addressed. These autol-
ogous chondrocytes could easily be genetically modified 
ex vivo – as shown, for example, for hematopoietic stem 
cells (143) – and could be implanted at the site of the car-
tilage defect, where a high concentration of the chondro-
genic agent is needed. For the transplantation of MSC it 
remains to be seen whether the terminal differentiation of 
chondrocytes when they become hypertrophic – as ob-
served in vitro – represents indeed a problem when im-
planted into articular cartilage defects in vivo (144,145).
Despite these encouraging data, application of genetically 
modified cells to treat cartilage defects is still not on the 
horizon. Issues that need to be addressed include the 
duration of transgene expression, extended studies 
with both nonviral and viral transfer systems in preclinical 
models of focal and osteoarthritic cartilage defects, the 
continuing elucidation of the benefit of using ex vivo ge-
netically modified cells vs direct gene transfer approach-
es, and the ongoing identification of optimal therapeutic 
factors. Future studies will also have to prove the safety of 
such approaches, since both traumatic defects and oste-
oarthritis are non-lethal diseases.
A key challenge in combining both experimental (in the 
case of genetic modification) and clinical knowledge (in 
the case of articular chondrocytes transplantation) and, as 
a result, to translate these progresses into clinical medicine 
is finally to establish a safe and efficient production line, 
including vector manufacturing, cell isolation, and genetic 
modification that meets all regulatory requirements.
Ultimately, the clinical potential for genetically modified 
articular chondrocytes and MSCs for the treatment of ar-
ticular cartilage defect is likely to be realized by advanc-
es in the following areas: 1) development of a safe, highly 
efficient gene delivery system with sustained duration of 
transgene expression, 2) identification of optimal thera-
peutic gene(s), 3) combination of genetically modified ar-
ticular chondrocytes and/or MSCs with scaffolds that bet-
ter support chondrogenesis in vivo. After safe techniques 
for generating these genetically engineered cells are avail-
able, such cells may eventually provide new avenues for 
improved cell-based therapies for articular cartilage repair. 
This, in turn, may provide a crucial step toward the unan-
swered question of articular cartilage regeneration.
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